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Background: Ventilator-associated tracheobronchitis (VAT) is
an important cause of mortality and morbidity in the hospitalized
patients in the ICUs. Appropriate and early onset antibiotic therapy
leads to better outcome. This study was conducted to determine
the frequency of bacterial agents and antimicrobial resistance, clin-
ical course and response to treatment of VAT in the hospitalized
patients in a surgical and a medical intensive care unit (ICU) of
teaching hospitals in Hamedan, Iran.
Methods & Materials: In a cross-sectional study in 2014, hos-
pitalized patients who had the criteria for the diagnosis of VAT
in medical ICU of Sina Hospital and surgical ICU of Besat Hospi-
tal in Hamedan were enrolled. Tracheal samples of patients were
investigated in terms of smear, culture and antibiotic sensitiv-
ity. Furthermore, demographic characteristics, underlyingdiseases,
clinical aspects, progression to pneumonia and response to the
treatmentwere collected by checklist. Datawere analyzed by using
SPSS-16.
Results: In this study, 69 patients were included, of whom,
28 patients (40/6%) were female and 41 (59/4%) were male. The
incidence of VAT was 6/44%. The mean age of the patients was
55/92±21/98 years. The most isolated bacteria consisted of Acine-
tobacter baumannii (30/4%), Pseudomonas aeruginosa (20/3%), and
Enterobacter (13%). In surgical ICU, Pseudomonas aeruginosa and
Enterobacter spp. were the most common isolates. In medical
ICU, Acinetobacter baumannii and Klebsiella pneumoniaewere the
most common bacteria. Over all, 63/3% of the isolates were mul-
tidrug resistant, outofwhich71%related to themedical ICUand29%
to the surgical ICU. All the isolates of Acinetobacter baumannii and
Citrobacter freundii were multidrug resistance. Also, 23 patients
(33/3%) progressed to pneumonia. The mean time of response to
treatment was 4/98±4.7 days, and 27/5% of the patients were dis-
charged after tracheostomy. Thirty-eight patients (98.6%) died in
spite of antimicrobial therapy.
Conclusion: Multidrug resistant pathogens are common causes
of VAT. A high proportion of VAT patients lead to pneumonia and
death. Considering the difference between the kind of pathogens
and antibiotic resistance in different ICUs, it is necessary to uti-
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Background: Infection is one of the major factors that deter-
mine clinical outcome among patients requiring intensive care unit
(ICU) support. The attending mortality is high and depends on
source of infection, organisms associated, timeliness and appro-
priateness of the treatment received.
Methods&Materials: Case recordsof patientswhowereadmit-
ted into our 5bedded ICU over a 4 year period were retrospectively
reviewed. The average number of admission was 20 per month.
A preformed questionnaire was administered and data on clini-
cal and microbiological proﬁle of all the patients with documented
infection was obtained.
Results: Eighty four episodes of infections were identiﬁed in
76 patients. Road trafﬁc accident 29/76(38.2%) and pulmonary
embolism12/76(15.8%) were the leading cause of admission. The
most common infection was skin and soft tissue infection (SSI)
30/84(35.7%) followedbyUTI 23/84(27.4) andprimarybacteraemia
18/84(21.4)with the leastbeingVAP3/84(3.6%).Mostof thecasesof
UTI occurred in patients with RTA and renal failure, while the high-
est number of primary bacteraemia was seen among patients with
burns and renal failure. The most frequent isolates were S. aureus
35/84(41.7%), K. pneumonia 18/84(21.4%) and E. coli 13/84(15.5%).
K. pneumonia 2/5(40%) and P. aerugenosa 1/5(20%)were the leading
cause of pneumonia, while S. aureus was the commonest cause of
SSI 16/30(53.3%), primary bacteremia 10/18(55.6%) and line infec-
tion 5/5(100%). There were 3 cases of VAP one each caused by
K. pneumonia, P. aerugenosa and S. aureus. High rate of resistance
to cloxacillin 19/35(54.3%) and co-trimoxazole 17/26(65.4%) was
noted among the S. aureus isolates. All the enterobactrecae isolates
that were tested against meropenem were fully susceptible, while
resistance rate to ceftriaxone was high; E. coli 5/9(55.6%), K. pneu-
moniae 10/14 (71.4%) and proteus spp 2/4 (50%). With exception to
meropenem and colistin, ciproﬂoxacin had a better resistance pro-
ﬁle against P. aerugenosa and isolated enterobactriacae compared
to the other tested B-lactam agents.
Conclusion: The study underscores the need to improve infec-
tion control practice in our ICU. Resistance to commonly used
antibiotic was high and this makes the choice of empiric antibi-
otic difﬁcult, hencemeasures to curtail the emergence of resistance
pathogens need to be adopted.
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